Testing two drugs for lower-risk MDS
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of MDS called lower-risk, with very low, low, or intermediate risk scores.
- You have had at least 2 red blood cell transfusions within the last 8 weeks, and you haven't gone more than 6 weeks without a transfusion during that time.
- Your bone marrow has less than 5% blasts (immature cells) from a recent biopsy.
- Your natural erythropoietin level is under 500 IU/L.
- You have not received certain prior treatments like ESAs, luspatercept, hypomethylating agents, or lenalidomide (with a few small exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.